Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News SAGE Therapeutics Inc SAGE

Healthcare Biotechnology
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SAGE)

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire 11 hours ago

Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress

Business Wire 22 hours ago

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Business Wire 8 days ago

Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024

Business Wire April 11, 2024

Sage Therapeutics to Present at Upcoming March Investor Conferences

Business Wire February 28, 2024

Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress

Business Wire February 14, 2024

Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024

Business Wire January 31, 2024

Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference

Business Wire January 8, 2024

Sage Therapeutics Announces Changes to Board of Directors

Business Wire January 8, 2024
View More News ››

Opinion & Analysis (NDAQ:SAGE)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SAGE)

Neurodegenerative Disorder-Focused Sage Therapeutics Stock F

JUST IN: $SAGE Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data...
whytestocks - 8 days ago

Neutral Recommendation Issued On SAGE By Goldman Sachs

BREAKING NEWS: $SAGE Neutral Recommendation Issued On SAGE By Goldman Sachs2024-04-17 12:30:03 ET Goldman Sachs analyst issues NEUTRAL...
whytestocks - 8 days ago

SAGE Price Target Alert: $22.00. Issued by Truist Financial

BREAKING NEWS: $SAGE SAGE Price Target Alert: $22.00. Issued by Truist Financial2024-04-17 12:00:02 ET Joon Lee from Truist Financial...
whytestocks - 8 days ago

Market Perform Recommendation Issued On SAGE By Raymond Jame

BREAKING NEWS: $SAGE Market Perform Recommendation Issued On SAGE By Raymond James2024-04-17 11:30:02 ET Raymond James analyst issues...
whytestocks - 8 days ago

J B Hunt Transport Reports Downbeat Earnings, Joins ASML And

JUST IN: $SAGE J B Hunt Transport Reports Downbeat Earnings, Joins ASML And Other Big Stocks Moving Lower In Wednesday's Pre-Market...
whytestocks - 8 days ago

Sage Therapeutics Announces Topline Results from Phase 2 PRE

NEWS: $SAGE Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild...
whytestocks - 8 days ago
View more Bullboard ››

Anfield Energy Inc

Anfield Energy Inc

Anfield Energy Inc. is a Canada-based uranium and vanadium development and near-term production company. A key asset in the ...
View More »